Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes-Reference-Cited by-全球学者库

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

Published:2015-04-20 Issue:5 Volume:21 Page:449-456
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Cristescu Razvan,Lee Jeeyun,Nebozhyn Michael,Kim Kyoung-Mee,Ting Jason C,Wong Swee Seong,Liu Jiangang,Yue Yong Gang^ORCID,Wang Jian,Yu Kun,Ye Xiang S,Do In-Gu,Liu Shawn,Gong Lara,Fu Jake,Jin Jason Gang,Choi Min Gew,Sohn Tae Sung,Lee Joon Ho,Bae Jae Moon,Kim Seung Tae,Park Se Hoon,Sohn Insuk,Jung Sin-Ho,Tan Patrick,Chen Ronghua,Hardwick James,Kang Won Ki,Ayers Mark,Hongyue Dai,Reinhard Christoph,Loboda Andrey,Kim Sung,Aggarwal Amit

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.3850.pdf

Reference50 articles.

1. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69–90 (2011).

2. Edge, S. et al. (eds.). AJCC Cancer Staging Manual (Springer, New York, 2010).

3. Lee, J. et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J. Clin. Oncol. 30, 268–273 (2012).

4. Kim, S. et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int. J. Radiat. Oncol. Biol. Phys. 63, 1279–1285 (2005).

5. Bang, Y.J. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379, 315–321 (2012).

Cited by 1482 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GCclassifier: An R package for the prediction of molecular subtypes of gastric cancer;Computational and Structural Biotechnology Journal;2024-12

2. Integrin-based prognostic model predicts survival, immunotherapy response, and drug sensitivity in gastric cancer;Biomedical Technology;2024-03

3. Identification of a lipid homeostasis-related gene signature for predicting prognosis, immunity, and chemotherapeutic effect in patients with gastric cancer;Scientific Reports;2024-02-05

4. Microsatellite instability in precancerous changes in the gastric mucosa;Kazan medical journal;2024-02-02

5. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion;Pathology - Research and Practice;2024-02